We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Voyager Therapeutics Inc | NASDAQ:VYGR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.17 | 2.03% | 8.53 | 8.05 | 8.60 | 8.65 | 8.27 | 8.65 | 435,860 | 23:00:02 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 18, 2016
Voyager Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
DELAWARE |
|
001-37625 |
|
46-3003182 |
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
75 Sidney Street
|
|
02139 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code (857) 259-5340
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02(b). Departure of Certain Officers.
On October 18, 2016, J. Jeffrey Goater, the Chief Financial Officer (Principal Financial and Accounting Officer) of Voyager Therapeutics, Inc. (the Company ), informed the Company that he will be resigning from his position on December 31, 2016, after which time he will serve as a consultant to the Company, while also pursuing other career opportunities.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 18, 2016 |
VOYAGER THERAPEUTICS, INC. |
|
|
|
|
|
By: |
/s/ Steven M. Paul |
|
|
Steven M. Paul, M.D. |
|
|
Chief Executive Officer and President |
1 Year Voyager Therapeutics Chart |
1 Month Voyager Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions